Compliance updated on Sep 10, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Taysha Gene Therapies, Inc.

TSHA ✓ COMPLIANTFree checks used up today ☆ Track — members

NASDAQ · Healthcare · Biotechnology & Medical Research ·

USA Small Cap Analyst: BUY

Last Close

$4.09

▲ +2.25%

Market Cap $1.33B · Vol 580.37K

Price charts are for members

Interactive price history from intraday to 5 years, on every stock and ETF.

See plans

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$1.33B

Small Cap

Div Yield

N/A

EPS Growth

-46.65%

YoY

RSI (14)

67.90

Momentum

Beta

1.32

vs Market

52W High

$7.30

43.97% below

52W Low

$3.46

18.21% above

Volume

580.37K

Avg 1.11M

P/B

6.35

Price-to-book

ROE

-68.45%

Return on equity

Free Float

89.99%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Taysha Gene Therapies, Inc. (TSHA) stock is Shariah compliant

You’ve used your 10 free compliance checks today

Choose a plan

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share.Members see the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does TSHA pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-3.76%

-11.66%

-29.24%

-35.39%

YTD

-25.64%

-8.30%

+64.92%

-75.54%

Financials & Valuation

TTM · Annual

Total Revenue	$9.77M
Net Income	$-108,995,000.00
Revenue Growth (YoY)	-100.00%
Gross Margin	100.00%
Operating Margin	-1,130.65%
Net Profit Margin	-1,115.27%
ROE	-68.45%
ROA · ROIC	-43.28% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	179.93
P/B	6.35
P/FCF	N/A
EPS Growth	-46.65%
Outstanding Shares	325.83M

Technical Indicators

50-Day SMA	$4.74
200-Day SMA	$5.32
RSI (14)	67.90
Beta	1.32
52-Week High	$7.30
52-Week Low	$3.46

Volume Today	580.37K
Avg Daily Volume (30D)	1.11M
Relative Volume	0.52x
Volatility (10D)	40.25
Volatility (30D)	69.54
Free Float	89.99%

Analyst Consensus

BUY

Current Price $4.09

Mean Target $13.00

52W Low$3.46 52W High$7.30

Current

Target

$3.46 $7.30

Current Analyst target

+217.85% upside potential · 13 analysts

Identifiers

ExchangeNASDAQ

FIGIBBG00TJXFDQ0

ISINUS8776191061

CountryUSA

Sub-IndustryBio Therapeutic Drugs

Earnings DateNov 2, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

2359.HK WuXi AppTec Co., Ltd. +12.39% ARGX.BR argenx SE +0.61% ARGX argenx SE +2.99% GMAB.CO Genmab A/S +0.57% GMAB Genmab A/S +1.09%

Company Profile

Taysha Gene Therapies Inc is a clinical-stage biotechnology company, which is focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system. The Company’s lead clinical program, TSHA-102, is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder. The Company is evaluating TSHA-102 in the REVEALPhase I/II adolescent and adult clinical trial, which is a first-in-human, open-label, randomized, dose escalation and dose-expansion, multicenter study evaluating the safety and preliminary efficacy of TSHA-102 in female patients aged 12-years and older with Rett syndrome. It has acquired a worldwide right to a clinical-stage, intrathecally dosed AAV9 gene therapy program, TSHA-120, for the treatment of giant axonal neuropathy (GAN). TSHA-105 is a gene replacement therapy in development for the treatment of SLC13A5 deficiency, a rare autosomal recessive epileptic encephalopathy.